Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Issues Quarterly Earnings Results

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) issued its earnings results on Thursday. The company reported $0.00 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07, FiscalAI reports. Lineage Cell Therapeutics had a negative net margin of 625.53% and a negative return on equity of 72.02%. The firm had revenue of $6.61 million during the quarter, compared to analyst estimates of $1.96 million.

Here are the key takeaways from Lineage Cell Therapeutics’ conference call:

• Lineage says its cash position of $55.8M plus recent warrant exercises (~$5.4M) and prior ATM proceeds extends its runway to Q2 2028, with an additional ~$32M of warrants outstanding not yet included.
• The company achieved an internal go/no-go on its islet cell research by demonstrating repeatable half‑liter “5D” manufacturing runs and plans to scale to multi‑liter vessels, prioritizing solving the supply/scale problem first.
• Progress on OpRegen was highlighted by Roche/Genentech opening 10 new GALE sites (17 total), RMAT designation and a $5M milestone payment to Lineage, which management frames as validation of the program and partner commitment.
• Full‑year 2025 net loss widened to $63.5M (vs. $18.6M in 2024), driven largely by non‑cash warrant fair‑value remeasurements and a material impairment charge, which materially increased reported operating losses.

Lineage Cell Therapeutics Stock Performance

Lineage Cell Therapeutics stock opened at $1.84 on Friday. Lineage Cell Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $2.09. The stock has a market cap of $423.81 million, a P/E ratio of -6.34 and a beta of 1.74. The firm’s fifty day moving average price is $1.72 and its 200-day moving average price is $1.64.

Analyst Ratings Changes

Several research firms recently commented on LCTX. D. Boral Capital reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, February 9th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, November 24th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $4.67.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC boosted its position in shares of Lineage Cell Therapeutics by 174.7% during the 4th quarter. Kestra Advisory Services LLC now owns 27,747 shares of the company’s stock valued at $46,000 after acquiring an additional 17,647 shares during the last quarter. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 9.9% in the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after purchasing an additional 18,092 shares in the last quarter. DLD Asset Management LP bought a new stake in Lineage Cell Therapeutics during the fourth quarter valued at approximately $33,000. Raymond James Financial Inc. grew its stake in Lineage Cell Therapeutics by 30.3% in the 3rd quarter. Raymond James Financial Inc. now owns 90,381 shares of the company’s stock worth $153,000 after buying an additional 21,001 shares in the last quarter. Finally, Jain Global LLC increased its holdings in shares of Lineage Cell Therapeutics by 202.3% in the 4th quarter. Jain Global LLC now owns 38,851 shares of the company’s stock worth $65,000 after buying an additional 26,000 shares during the last quarter. 62.47% of the stock is currently owned by institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.